Press Releases

Press Releases

October 15, 2019
First ever prospective randomized multicenter clinical utility study shows the favorable impact of AVISE® Lupus on clinical decision-making and patient management SAN DIEGO , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum
September 18, 2019
San Diego, CA, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),  an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention,
July 16, 2019
San Diego, CA and Albuquerque, NM, July 16, 2019 (GLOBE NEWSWIRE) -- Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis, prognosis, and monitoring while
April 24, 2019
Lupus Patients with Elevated PC4d Levels Have Significantly Increased Occurrence of Thrombosis San Diego, CA and Albuquerque, NM, April 24, 2019 (GLOBE NEWSWIRE) -- Exagen Inc., a leader in helping rheumatologist and their patients in the diagnosis, prognosis, and management of chronic autoimmune
March 26, 2019
Jeff Elliott adds relevant experience to Exagen’s Board of Directors as a former diagnostics analyst at Robert W. Baird & Co. as well as the current CFO of Exact Sciences San Diego, CA and Albuquerque, NM, March 26, 2019 (GLOBE NEWSWIRE) -- Exagen Inc., an organization dedicated to transforming the
Displaying 1 - 10 of 13